ELMIRON SIDE EFFECTS
- Generic Name: pentosan polysulfate sodium capsules
- Brand Name: Elmiron
SIDE EFFECTS
ELMIRON® was evaluated in clinical trials in a total of 2627 patients (2343 women, 262 men, 22 unknown) with a mean age of 47 [range 18 to 88 with 581 (22%) over 60 years of age]. Of the 2627 patients, 128 patients were in a 3-month trial and the remaining 2499 patients were in a long-term, unblinded trial.
Deaths occurred in 6/2627 (0.2%) patients who received the drug over a period of 3 to 75 months. The deaths appear to be related to other concurrent illnesses or procedures, except in one patient for whom the cause was not known.
Serious adverse events occurred in 33/2627 (1.3%) patients. Two patients had severe abdominal pain or diarrhea and dehydration that required hospitalization. Because there was not a control group of patients with interstitial cystitis who were concurrently evaluated, it is difficult to determine which events are associated with ELMIRON® and which events are associated with concurrent illness, medicine, or other factors.
Adverse Experience in Placebo-Controlled Clinical Trials of ELMIRON® 100 mg Three Times a Day for 3 Months
Body System/Adverse Experience | ELMIRON® n=128 |
Placebo n=130 |
CNS Overall Number of Patients* | 3 | 5 |
Insomnia | 1 | 0 |
Headache | 1 | 3 |
Severe Emotional Lability/Depression | 2 | 1 |
Nystagmus/Dizziness | 1 | 1 |
Hyperkinesia | 1 | 1 |
GI Overall Number of Patients* | 7 | 7 |
Nausea | 3 | 3 |
Diarrhea | 3 | 6 |
Dyspepsia | 1 | 0 |
Jaundice | 0 | 1 |
Vomiting | 0 | 2 |
Skin/Allergic Overall Number of Patients* | 2 | 4 |
Rash | 0 | 2 |
Pruritus | 0 | 2 |
Lacrimation | 1 | 1 |
Rhinitis | 1 | 1 |
Increased Sweating | 1 | 0 |
Other Overall Number of Patients* | 1 | 3 |
Amenorrhea | 0 | 1 |
Arthralgia | 0 | 1 |
Vaginitis | 1 | 1 |
Total Events | 17 | 27 |
Total Number of Patients Reporting Adverse Events | 13 | 19 |
* Within a body system, the individual events do not sum to equal overall number of patients because a patient may have more than one event. |
The adverse events described below were reported in an unblinded clinical trial of 2499 interstitial cystitis patients treated with ELMIRON®. Of the original 2499 patients, 1192 (48%) received ELMIRON® for 3 months; 892 (36%) received ELMIRON® for 6 months; and 598 (24%) received ELMIRON® for one year, 355 (14%) received ELMIRON® for 2 years, and 145 (6%) for 4 years.
Frequency (1 to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%).
Frequency (≤ 1%):
Digestive: Vomiting, mouth ulcer, colitis, esophagitis, gastritis, flatulence, constipation, anorexia, gum hemorrhage.
Hematologic: Anemia, ecchymosis, increased prothrombin time, increased partial thromboplastin time, leukopenia, thrombocytopenia.
Hypersensitive Reactions: Allergic reaction, photosensitivity.
Respiratory System: Pharyngitis, rhinitis, epistaxis, dyspnea.
Skin and Appendages: Pruritus, urticaria.
Special Senses: Conjunctivitis, tinnitus, optic neuritis, amblyopia, retinal hemorrhage.
Post-Marketing Experience
The following adverse reactions have been identified during post approval use of pentosan polysulfate sodium; because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:
- pigmentary changes in the retina.
Rectal Hemorrhage
ELMIRON® was evaluated in a randomized, double-blind, parallel group, Phase 4 study conducted in 380 patients with interstitial cystitis dosed for 32 weeks. At a daily dose of 300 mg (n=128), rectal hemorrhage was reported as an adverse event in 6.3% of patients. The severity of the events was described as “mild” in most patients. Patients in that study who were administered ELMIRON® 900 mg daily, a dose higher than the approved dose, experienced a higher incidence of rectal hemorrhage, 15%.
Liver Function Abnormality
A randomized, double-blind, parallel group, Phase 2 study was conducted in 100 men (51 ELMIRON® and 49 placebo) dosed for 16 weeks. At a daily dose of 900 mg, a dose higher than the approved dose, elevated liver function tests were reported as an adverse event in 11.8% (n=6) of ELMIRON®-treated patients and 2% (n=1) of placebo-treated patients.
SRC: NLM .